Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
A phase 1/2 trial of Osimertinib in non-small-cell lung cancer, run by Genprex, Inc., now recruiting.
Overview
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib is a phase 1/2 interventional study registered as NCT04486833 by Genprex, Inc., with 158 participants planned, started 2021-09-03 and due to reach its primary completion in 2028-03. Interventions recorded: quaratusugene ozeplasmid, osimertinib and Platinum-Based Chemotherapy.
Similar pages
not linked directly; found by shared links- TrialA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialJMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialOleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialTY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialOsimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Shares Osimertinib and the tag pipeline.
- TrialA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Shares Osimertinib, Non-small-cell lung cancer and the tag pipeline.